Bayer World Investments B.V. - Oct 13, 2021 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Former 10% Owner
Signature
Bayer World Investments B.V., By: /s/ Patrick Lennaerts, Name: Patrick Lennaerts, Title: Managing Director
Stock symbol
PYXS
Transactions as of
Oct 13, 2021
Transactions value $
$0
Form type
4
Date filed
10/15/2021, 05:05 PM
Previous filing
Oct 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PYXS Common Stock Conversion of derivative security +2.74M 2.74M Oct 13, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Series A Convertible Preferred Stock Conversion of derivative security -11.4M -100% 0 Oct 13, 2021 Common Stock 1.79M Direct F1, F2
transaction PYXS Series B Convertible Preferred Stock Conversion of derivative security -6.08M -100% 0 Oct 13, 2021 Common Stock 956K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Bayer World Investments B.V. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.
F2 The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.